Colonel William A. Phillips

Edit links

Sunobinop (developmental code name IMB-115) is a nociceptin receptor partial agonist and opioid receptor pan-antagonist.[1] As of March 2022, it is under investigation for the treatment of insomnia,[2] fibromyalgia, and overactive bladder.[1][3]

See also

References

  1. ^ a b "Sunobinop - Shionogi/Imbrium Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Whiteside GT, Kyle DJ, Kapil RP, Cipriano A, He E, Zhou M, et al. (January 2024). "The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia". The Journal of Clinical Investigation. 134 (1). doi:10.1172/JCI171172. PMC 10760950. PMID 37883189.
  3. ^ WO application 2018020418, Harris SC, Kapil RP, Kyle DJ, Whiteside G, "Treatment and prevention of sleep disorders", published 2018-02-01, assigned to Purdue Pharma L.P. 



source: https://en.wikipedia.org/wiki/Sunobinop